Cliniques universitaires Saint-Luc

Brussels, Belgium

21 recruiting

Showing 120 of 47 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis
Bristol-Myers Squibb366 enrolled127 locationsNCT06979453
Recruiting
Phase 2

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Acute Lymphoblastic Leukemia
Pfizer100 enrolled74 locationsNCT05748171
Recruiting
Phase 1

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

Advanced Solid Tumor (Phase 1)
Epics Therapeutics48 enrolled11 locationsNCT07163325
Recruiting
Phase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Diabetes Mellitus, Type 1
Eli Lilly and Company150 enrolled107 locationsNCT07222137
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled132 locationsNCT07222332
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled140 locationsNCT06615479
Recruiting
Phase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis+1 more
Eli Lilly and Company150 enrolled67 locationsNCT04844606
Recruiting
Phase 3

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled752 locationsNCT07157774
Recruiting
Phase 2

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Advanced Breast CancerHormone Receptor-Positive Breast CarcinomaAdvanced Breast Carcinoma
MedSIR200 enrolled72 locationsNCT06486883
Recruiting
Phase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled353 locationsNCT06875310
Recruiting
Phase 3

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

ObesityType 2 Diabetes
Novo Nordisk A/S2,500 enrolled303 locationsNCT07564414
Recruiting
Phase 2Phase 3

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled286 locationsNCT07221357
Recruiting
Phase 3

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Crohn's Disease
Eli Lilly and Company90 enrolled81 locationsNCT05509777
Recruiting
Phase 3

Personalized Medicine for Advanced Biliary Cancer Patients

Biliary Tract Neoplasms
UNICANCER800 enrolled69 locationsNCT05615818
Recruiting
Phase 3

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis
Eli Lilly and Company190 enrolled80 locationsNCT03773965
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Breast Cancer
Pfizer400 enrolled202 locationsNCT07062965
Recruiting
Not Applicable

Comparison Between Different Interdental Brushes in Adults With Periodontal Disease.

Periodontal Disease
Pierre Fabre Dermo Cosmetique88 enrolled1 locationNCT07575997
Recruiting
Phase 2Phase 3

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled279 locationsNCT07076121